AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1680893
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (250 micrograms/h for 24 hours)
Trial: 1680893
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of somatostatin and balloon tamponade
Trial: 10896067
Drug: Intravenous secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous secretin (2 U/kg) plus placebo (Group 1)
Trial: 10896067
Drug: Intravenous secretin
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous secretin (2 U/kg) plus cholecystokinin (0.02 microg/kg) (Group 2)
Trial: 9378668
Drug: Homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic treatment (Nux vomica D200, Okoubaka D3, Tuberculinum D200, Barium jodatum D4, Barium jodatum D6)
Trial: 8317516
Drug: OC3 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC3 (35 micrograms ethinyl estradiol and 0.5 mg norethindrone)
Trial: 8317516
Drug: OC2 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC2 (35 micrograms ethinyl estradiol and 1.0 mg norethindrone)
Trial: 24528935
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyaluronate and diquafosol
Trial: 22238339
Drug: DepoFoam bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoFoam bupivacaine (133 or 266 mg)
Trial: 22238339
Drug: bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine HCl (75 mg)
Trial: 22238339
Drug: bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine HCl (200 mg)
Trial: 22238339
Drug: DepoFoam bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DepoFoam bupivacaine (532 mg)
Trial: 19279561
Drug: NIC gum
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIC gum treatment
Trial: 17192761
Drug: STS 6
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: STS 6 mg/24 hr
Trial: 15923689
Drug: Zinc and
RxNorm normalized name: Zinc and/or zinc compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc and copper supplementation (40 mg of zinc sulfate and 5 mg of copper sulfate in ORS)
Trial: 15923689
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mg of standard ORS powder in ORS)
Trial: 12414874
Drug: Aspirin (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (a nonspecific COX‐1 and COX‐2 inhibitor)
Trial: 12414874
Drug: Diclofenac (predominantly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (predominantly a COX‐2 inhibitor)
Trial: 12414874
Drug: Celecoxib (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (a specific COX‐2 inhibitor)
Trial: 755865
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of autogenic training and skin temperature feedback
Trial: 31127818
Drug: Carbohydrate or
RxNorm normalized name: PHOSPHORATED CARBOHYDRATE ORAL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate or protein delivered in gastric release formulations
Trial: 31127818
Drug: Fat delivered
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat delivered in gastric release formulations
Trial: 29220633
Drug: treatment‐as‐usual condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment‐as‐usual condition
Trial: 26011337
Drug: Postoperative parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative parenteral nutrition (PN)
Trial: 23420502
Drug: Oral ergocalciferol
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ergocalciferol
Trial: 21289227
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) levels measured in quartiles and clinical cut points (<50, 50-<75, ≥ 75 nmol/L)
Trial: 22078129
Drug: Rizatriptan 10-mg
RxNorm normalized name: rizatriptan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 10-mg ODT
Trial: 11679918
Drug: Diphtheria-tetanus toxoids-acellular
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria-tetanus toxoids-acellular pertussis (DTaP) combined with PRP-tetanus conjugate (PRP-T) vaccine
Trial: 7841965
Drug: Both drug
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drug and surgical treatment (endometrial resection or hysterectomy)
Trial: 30251598
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg single oral dose
Trial: 27440518
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg edoxaban
Trial: 27440518
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg edoxaban
Trial: 23448939
Drug: Phytonutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytonutrient supplement (blended fruit and vegetable juice powder concentrate)
Trial: 23448939
Drug: Phytonutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytonutrient supplement
Trial: 20873911
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) group (n = 42)
Trial: 20873911
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) group (n = 74)
Trial: 28763413
Drug: Motor-sparing block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor-sparing block (0.5% ropivacaine, 2.5 μg/mL of epinephrine, 10 mg of morphine, and 30 mg of ketorolac)
Trial: 28763413
Drug: Periarticular infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration (0.3% ropivacaine, 2.5 μg/mL of epinephrine, 10 mg of morphine, and 30 mg of ketorolac)
Trial: 23347176
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 mg every other day plus folic acid 5 mg daily
Trial: 23347176
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 mg every other day plus placebo daily
Trial: 17912163
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (under investigation)
Trial: 12786728
Drug: Deodorants containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deodorants containing hydroxycitronellal (0.032-0.32%) applied twice daily
Trial: 1761173
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oestriol applied daily intravaginally over 3 weeks
Trial: 1761173
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg oestriol applied daily intravaginally over 3 weeks
Trial: 24366034
Drug: Combination (weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (weight loss and sodium reduction)
Trial: 23158073
Drug: nCPAP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP + antihypertensive drugs
Trial: 20490904
Drug: Hydralazine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine therapy (25 mg b.d., for 1 week)
Trial: 20490904
Drug: Hydralazine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine therapy
Trial: 18300848
Drug: Valsartan 80-160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80-160 mg/day
Trial: 16113620
Drug: Atomoxetine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine monotherapy
Trial: 16113620
Drug: Combined atomoxetine/fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined atomoxetine/fluoxetine therapy
Trial: 16113620
Drug: Fluoxetine (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (with concomitant atomoxetine)
Trial: 12885837
Drug: 30-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion of gemcitabine (2,200 mg/m2)
Trial: 12885837
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose rate (FDR) infusion of gemcitabine (1,500 mg/m2 over 150 minutes)
Trial: 10389788
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone 8 mg
Trial: 8782169
Drug: Selective adsorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective adsorption followed by intravenous IgG
Trial: 6344265
Drug: Diazepam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.05 mg/kg
Trial: 30642575
Drug: BET inhibitor
RxNorm normalized name: BET INHIBITOR TEN-010
DrugBank: RO-6870810 (DB15151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BET inhibitor (JQ1)
Trial: 29551706
Drug: Glecaprevir/pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (G/P) for 8 weeks (300 mg/120 mg)
Trial: 29551706
Drug: Glecaprevir/pibrentasvir (G/P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (G/P) for 12 weeks (300 mg/120 mg)
Trial: 22828556
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ringer's Lactate 10ml/kg and Hydroxyethylstarch-6% 4ml/kg (Group-RLH)
Trial: 17490966
Drug: Trace element
RxNorm normalized name: trace elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trace element supplementation (copper, selenium, zinc) administered intravenously for 14-21 days.
Trial: 15561864
Drug: BB-83698 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BB-83698 (10 to 475 mg single dose)
Trial: 8526579
Drug: Carbohydrate-rich drink
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich drink (400 mL, 285 mOsm/kg, 12.0% carbohydrates)
Trial: 8526579
Drug: Water (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (400 mL)
Trial: 26336930
Drug: Belimumab treatment
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab treatment
Trial: 25403582
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg every 6 months for 3 years) plus tamoxifen (20 mg/day)
Trial: 25403582
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg every 6 months for 3 years) plus anastrozole (1 mg/day)
Trial: 11132749
Drug: Nicardipine 0.017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 0.017 mg x kg(‐1) administered as a bolus
Trial: 8406060
Drug: Nicotine (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (2-4 mg in gum base)
Trial: 3778815
Drug: Behavioural method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural method of habit reversal combined with hydrocortisone cream
Trial: 3778815
Drug: Regular ointment
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular ointment treatment (hydrocortisone cream alone)
Trial: 30081859
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg per night of capsulated sustained-release melatonin (Circadin)
Trial: 30081859
Drug: 1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule
Trial: 27274009
Drug: Pradigastat (115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat (115 mg intravenously)
Trial: 27274009
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg oral, positive control)
Trial: 25738335
Drug: Conical interface
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conical interface (CI; OsseoSpeed, Dentsply Implants), n = 4
Trial: 21840915
Drug: telephone cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telephone cognitive behavioural therapy emphasizing physical activity
Trial: 19842352
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment consisting of stretching, posture training, and auricular acupuncture
Trial: 15231974
Drug: Early-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-treatment group (M&T performed promptly)
Trial: 15231974
Drug: Late-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-treatment group (M&T performed after a defined extended period)
Trial: 11409520
Drug: 5000 U
RxNorm normalized name: lipase 5000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 U of heparin
Trial: 8591483
Drug: Improved access
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved access to medication
Trial: 2475710
Drug: Isradipine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5, 5, and 7.5 mg b.i.d. every 3rd week)
Trial: 31148210
Drug: Enteral dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral dextrose infusion for 24 hours (n=30)
Trial: 31148210
Drug: Water (placebo)
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (placebo) infusion for 24 hours (n=30)
Trial: 25906706
Drug: NCH gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCH gel
Trial: 24742116
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (CBT)
Trial: 22948406
Drug: TeleFamilies intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TeleFamilies intervention with advanced practice nurse as care coordinator; details on dosage and duration not specified.
Trial: 16200556
Drug: Hospital chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital chemotherapy
Trial: 15785179
Drug: Endovascular therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapies (angioplasty, stenting, endoluminal stent grafts)
Trial: 8497821
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate with a 750 ml spacer (group S)
Trial: 8497821
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups at 2 mg/day of beclomethasone dipropionate
Trial: 20810877
Drug: Aphasia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphasia treatment targeting anomia (30 hours of treatment)
Trial: 20810877
Drug: Aphasia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aphasia treatment targeting anomia
Trial: 18438689
Drug: Topical morphine
RxNorm normalized name: morphine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical morphine (0.1%, 0.2%, 0.4%)
Trial: 18438689
Drug: Topical buprenorphine
RxNorm normalized name: buprenorphine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical buprenorphine (0.01%, 0.02%, 0.1%)
Trial: 15958804
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m² IV on days 1, 4, 8, and 11 for eight three-week cycles, then days 1, 8, 15, and 22 for three five-week cycles)
Trial: 15958804
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (40 mg orally on days 1-4, 9-12, and 17-20 for four five-week cycles, then days 1-4 for five four-week cycles)
Trial: 10643226
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with insulin and metformin
Trial: 8896734
Drug: Cyclosporine and
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine and steroid immunosuppressive therapy (CSA regimen)
Trial: 8896734
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporine (4 mg/kg/day), steroid therapy, and 21-day course of 500 mg/day antilymphocyte globulin (ALG 1 regimen)
Trial: 8896734
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporine (6 mg/kg/day), steroid therapy, and 14-day course of 1,000 mg/day antilymphocyte globulin (ALG 2 regimen)
Trial: 8896734
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporine (6 mg/kg/day), steroid therapy, and 14-day course of 1,000 mg/day antilymphocyte globulin followed by 2 mg/kg/day mizoribine (ALG 3 regimen)
Trial: 8896734
Drug: FK506 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 and steroid therapy (FK506 regimen)
Trial: 8896734
Drug: Cyclosporine and
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine and steroid therapy
Trial: 24553695
Drug: Echium oil
RxNorm normalized name: Echium plantagineum seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echium oil (EO) 17 g/d (2 g SDA)
Trial: 24553695
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) 17 g/d (1.9 g EPA)
Trial: 23249501
Drug: Adjunctive rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive rifampicin (600-900 mg/day; orally or intravenously)
Trial: 20456738
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg daily
Trial: 18215589
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stents (DESs)
Trial: 16199841
Drug: Community-delivered psychodynamic
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-delivered psychodynamic therapy
Trial: 14520722
Drug: 25‐OH‐vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐OH‐vitamin D (cholecalciferol) 15 microg (600 IU) once daily
Trial: 11220352
Drug: Acarbose (half
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (half a pill before lunch and half a pill before dinner)
Trial: 1856305
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel 2%
Trial: 1856305
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride gel 1.25%
Trial: 1856305
Drug: Stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stannous fluoride gel 4%
Trial: 7174305
Drug: Pizotifen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen 0.5 mg t.d.s.
Trial: 7174305
Drug: Pizotifen 1.5
RxNorm normalized name: Pizotifen 1.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen 1.5 mg nocte
Trial: 31214178
Drug: Tadalafil and
RxNorm normalized name: finasteride and tadalafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil and MUC1/polyICLC vaccine
Trial: 2499203
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg praziquantel
Trial: 28174906
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg praziquantel
Trial: 28174906
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 25 mg/kg praziquantel
Trial: 15116254
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH) thromboprophylaxis
Trial: 11668032
Drug: Neostigmine (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.25, 0.75, or 1.5 mg)
Trial: 11668032
Drug: Bethanechol (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (2.5, 5, or 10 mg)
Trial: 28763881
Drug: Memantine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine combined Reinhartdt And Sea Cucumber Capsule (R.S.C)